Although p53 mutations are rare in MM (only 10% of the diagnosed patients) [69], patients harboring the 17p13 deletion [del(17p)] are considered “high risk” and have poorer outcomes and shorter survival times compared to standard-risk patients [70,71,72]. This evidence concerns the gene TP53 and Miyoshi myopathy.